CASSIOPEA Study

Because idraparinux has a very long duration of action, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of the biotin moiety would allow the rapid removal of the drug  upon the addition of avidin. A bioequipotency study of biotinylated idraparinux vs. idraparinux for the treatment of DVT is currently  ongoing, and patients are being recruited into the phase III CASSIOPEA  study of biotinylated idraparinux vs. warfarin for the treatment of PE.